According to a document disclosed by the U.S. Securities and Exchange Commission (SEC) on February 17, 2026, renowned investment institution Casdin Capital adjusted its position in the biotechnology company Structure Therapeutics (GPCR) during the fourth quarter of last year, reducing its holdings by 380,000 shares. Based on the average stock price for that quarter, the value of this reduction transaction is estimated to be approximately USD 15.52 million. Influenced by a combination of trading activities and changes in market value, the overall value of the fund’s position in Structure Therapeutics held at the end of the quarter decreased by USD 38.18 million.
Following this reduction, Structure Therapeutics’ proportion in Casdin Capital’s investment portfolio, as disclosed in the 13F report submitted to the SEC, dropped to 5.08%. The document also reveals the fund’s top five heavyweight holdings as of the end of the quarter, all of which are companies in the biotechnology sector, indicating its sustained confidence in this industry. These holdings include: As of the disclosure date, holding shares in DNA sequencing company Ginkgo Bioworks Holdings (WGS) valued at USD 391.11 million, accounting for 24.3% of the portfolio; holding shares in cancer drug developer Revolution Medicines (RVMD) worth USD 205.28 million, representing 12.8%; holding shares in bioprocessing technology company BioLife Solutions (BLFS) valued at USD 144.04 million, accounting for 8.9%; holding shares in life sciences tools company Standard BioTools (LAB) worth USD 113.64 million, representing 7.1%; and holding shares in genetic medicine company Relay Therapeutics (RLAY) valued at USD 110.01 million, accounting for 6.8%.
Despite the reduction by a major fund, Structure Therapeutics’ stock price performance remains striking. As of February 17, 2026, the company’s shares closed at USD 71.41, with a cumulative increase over the past year reaching an astonishing 214.3%, significantly outperforming the S&P 500 index by a margin of 180.87 percentage points.
Structure Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative oral therapies for chronic diseases. Leveraging its expertise in G protein-coupled receptor (GPCR) drug discovery, the company has built a research and development pipeline centered around its lead candidate, GSBR-1290. This drug primarily targets type 2 diabetes and obesity, while the company is also advancing research programs for pulmonary and cardiovascular diseases. Its business model involves creating value through development and potential out-licensing or commercialization collaborations. As all products are still in the clinical trial stage, the company has not yet generated revenue. The company aims to serve patients with chronic metabolic, pulmonary, and cardiovascular diseases, addressing the significant unmet medical needs in these areas.
Regarding this transaction, market analysis suggests that when a biotechnology stock surges by over 200% within a year, an investment institution’s decision to reduce its position is often more related to portfolio management considerations rather than a loss of confidence in the drug’s development prospects. For long-term investors, the key lies in whether its oral GLP-1 therapy can capture a significant share in the obesity treatment market. The results of the upcoming Phase 3 clinical trials will be crucial in determining its long-term value.
